Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 15, 2019
Daily News
November 15, 2019
- Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President
November 15, 2019
- Big 3 Generic Firms Enjoy 7.8% Growth, AG Makers Triumph: Jiho Tally
November 15, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely
November 15, 2019
- Only 2.4% of Pharmacies Have Generic Drug Formularies in Their Region: Tokyo Govt Survey
November 15, 2019
- Fujifilm to Make 13 Billion Yen Investment in Gene Therapy Facilities in US
November 15, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…